;R1, R2, R3, R4 and R7 are independently H, halo, alkyloxyl, alkyl or hydroxyl, provided that one of R1, R2, R3 and R7 is X—(CH2)n—R8; R5 is alkyl or arylalkyl; R6 is H or alkyl; X is a bond, O, S, SO, SO2, CO or NH; n=0-10; R8 is alkenyl, substituted or unsubstituted aryl, NR9R10, or OR9; R9 is H, substituted or unsubstituted arylmethyl, or alkenyl; and R10 is H or alkyl."/>
ISOQUINOLONE COMPOUNDS AS SUBTYPE-SELECTIVE AGONISTS FOR MELATONIN RECEPTORS MT1 AND MT2
首页>
外国专利>
ISOQUINOLONE COMPOUNDS AS SUBTYPE-SELECTIVE AGONISTS FOR MELATONIN RECEPTORS MT1 AND MT2
ISOQUINOLONE COMPOUNDS AS SUBTYPE-SELECTIVE AGONISTS FOR MELATONIN RECEPTORS MT1 AND MT2
展开▼
机译：异喹啉酮类化合物作为褪黑激素受体MT1和MT2的亚型选择性激动剂
展开▼
页面导航
摘要
著录项
相似文献
摘要
A method of treating, preventing, or ameliorating a pathological condition associated with a melatonin receptor in a mammal by using a pharmaceutical composition containing a compound of formula (I) as a ligand interacting with the melatonin receptor,; ;R1, R2, R3, R4 and R7 are independently H, halo, alkyloxyl, alkyl or hydroxyl, provided that one of R1, R2, R3 and R7 is X—(CH2)n—R8; R5 is alkyl or arylalkyl; R6 is H or alkyl; X is a bond, O, S, SO, SO2, CO or NH; n=0-10; R8 is alkenyl, substituted or unsubstituted aryl, NR9R10, or OR9; R9 is H, substituted or unsubstituted arylmethyl, or alkenyl; and R10 is H or alkyl.
展开▼
机译：一种通过使用包含式（I）的化合物作为与褪黑激素受体相互作用的配体的药物组合物来治疗，预防或改善哺乳动物中与褪黑激素受体相关的病理状况的方法; ; R 1 ，R 2 ，R 3 ，R 4 和R 7 独立地为H，卤素，烷氧基，烷基或羟基，条件是R 1 ，R 2 ，R 3 和R 之一7 是X-（CH 2 ） n -R 8 ; R 5 是烷基或芳基烷基; R 6 是H或烷基; X为键，O，S，SO，SO 2 ，CO或NH; n = 0 - 10 ; R 8 是烯基，取代或未取代的芳基，NR 9 R 10 或OR 9 ; R 9 是H，取代或未取代的芳基甲基或烯基; R 10 是H或烷基。
展开▼
